Beijing Genomics Institute (BGI) is one of the world's leading genomics research institutions, based in Beijing, China. Established in 1999, BGI is recognized for its significant contributions to genomic research, technological innovation, and large-scale sequencing projects.
BGI focuses on various aspects of genomics research, including genome sequencing, functional genomics, epigenomics, and bioinformatics. The institute utilizes cutting-edge technologies and interdisciplinary approaches to investigate genetic variations, gene functions, and the impact of genomics on human health, biological diversity, and other related fields.
BGI's primary mission involves advancing scientific knowledge and promoting the application of genomics for the betterment of human health and other important areas. Its research projects encompass a wide range of species, from microorganisms and plants to animals and humans, targeting both common and rare genetic diseases, cancer genomics, and pharmacogenomics.
With its extensive sequencing capabilities, BGI has played a significant role in numerous groundbreaking initiatives, including the 1,000 Genomes Project, the China National GeneBank, and the International Cancer Genome Consortium. BGI has also been at the forefront of public health crises, providing rapid sequencing and analysis during outbreaks of infectious diseases such as SARS, H1N1, and COVID-19.
As a global leader in genomics, BGI collaborates extensively with research institutions, universities, and medical organizations worldwide, contributing to international efforts and partnerships that drive scientific discovery, technological advancements, and the translation of genomics into practical applications for human welfare.
